50 related articles for article (PubMed ID: 17109516)
1. Efficacy and Safety of Thalidomide for Chemotherapy-induced Nausea and Vomiting.
Wang N; Xu P; Liu Y; Zhao P; Ruan J; Zheng Y; Jin J; Wang S; Yao J; Xiang D; Zhang D; Li N; Kang H; Dai Z
J Cancer; 2020; 11(15):4560-4570. PubMed ID: 32489473
[No Abstract] [Full Text] [Related]
2. Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach.
Yang W; Wang D; Huang L; Chen Y; Wen S; Hong Q; Kang D
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2043-2055. PubMed ID: 30139041
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis.
Cao DD; Xu HL; Liu L; Zheng YF; Gao SF; Xu XM; Ge W
Oncotarget; 2017 Jul; 8(27):44976-44993. PubMed ID: 28402958
[TBL] [Abstract][Full Text] [Related]
4. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma.
Ch'ang HJ
World J Hepatol; 2015 Aug; 7(16):2029-40. PubMed ID: 26261692
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action.
Shaaban S; Negm A; Ibrahim EE; Elrazak AA
Oncol Rev; 2014 Mar; 8(1):246. PubMed ID: 25992234
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: An Indian experience.
Pande SB; Doval DC; Pavithran K; Sharma JB; Shirali R; Jena A
Indian J Med Paediatr Oncol; 2012 Jan; 33(1):42-7. PubMed ID: 22754208
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide treatment in cirrhotic patients with severe anemia secondary to vascular malformations.
Garrido Serrano A; León R; Sayago M; Márquez JL
Dig Dis Sci; 2012 Apr; 57(4):1112-3. PubMed ID: 22089255
[No Abstract] [Full Text] [Related]
8. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.
Omata M; Lesmana LA; Tateishi R; Chen PJ; Lin SM; Yoshida H; Kudo M; Lee JM; Choi BI; Poon RT; Shiina S; Cheng AL; Jia JD; Obi S; Han KH; Jafri W; Chow P; Lim SG; Chawla YK; Budihusodo U; Gani RA; Lesmana CR; Putranto TA; Liaw YF; Sarin SK
Hepatol Int; 2010 Mar; 4(2):439-74. PubMed ID: 20827404
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.
Shen YC; Hsu C; Cheng AL
J Gastroenterol; 2010 Aug; 45(8):794-807. PubMed ID: 20567987
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma: management of an increasingly common problem.
Davis GL; Dempster J; Meler JD; Orr DW; Walberg MW; Brown B; Berger BD; O'Connor JK; Goldstein RM
Proc (Bayl Univ Med Cent); 2008 Jul; 21(3):266-80. PubMed ID: 18628926
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma with intra-atrial tumor thrombi. A report of three cases responsive to thalidomide treatment and literature review.
Chang JY; Ka WS; Chao TY; Liu TW; Chuang TR; Chen LT
Oncology; 2004; 67(3-4):320-6. PubMed ID: 15557794
[TBL] [Abstract][Full Text] [Related]
13. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.
Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK
Leuk Lymphoma; 2003 Jul; 44(7):1147-9. PubMed ID: 12916866
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.
Chiou HE; Wang TE; Wang YY; Liu HW
World J Gastroenterol; 2006 Nov; 12(43):6955-60. PubMed ID: 17109516
[TBL] [Abstract][Full Text] [Related]
15. Low-dose thalidomide treatment for advanced hepatocellular carcinoma.
Hsu C; Chen CN; Chen LT; Wu CY; Yang PM; Lai MY; Lee PH; Cheng AL
Oncology; 2003; 65(3):242-9. PubMed ID: 14657598
[TBL] [Abstract][Full Text] [Related]
16. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
